Abstract：
The 2022 mpox outbreak led the World Health Organization (WHO) to declare it a public health emergency of international concern (PHEIC). There is a need to develop more effective and safer mpox virus (MPXV)-specific vaccines in response to the mpox epidemic. The mRNA vaccine is a promising platform to protect against MPXV infection. In this study, we construct two bivalent MPXV mRNA vaccines, designated LBA (B6R-A29L) and LAM (A35R-M1R), and a quadrivalent mRNA vaccine, LBAAM (B6R-A35R-A29L-M1R). The immunogenicity and protective efficacy of these vaccines alone or in combination were evaluated in a lethal mouse model. All mRNA vaccine candidates could elicit potential antigen-specific humoral and cellular immune responses and provide protection against vaccinia virus (VACV) infection. The protective effect of the combination of two bivalent mRNA vaccines and the quadrivalent vaccine was superior to that of the individual bivalent mRNA vaccine. Our study provides valuable insights for the development of more efficient and safer mRNA vaccines against mpox.
摘要：
2022年的水痘疫情导致世界卫生组织（WHO）宣布其为国际关注的突发公共卫生事件（PHEIC）。需要开发更有效和更安全的痘病毒(MPXV)特异性疫苗以响应痘病毒流行。mRNA疫苗是防止MPXV感染的有前途的平台。在这项研究中,我们构建了两种二价MPXVmRNA疫苗，指定LBA(B6R-A29L)和LAM(A35R-M1R),和四价mRNA疫苗，LBAAM(B6R-A35R-A29L-M1R)。在致死小鼠模型中评价这些疫苗单独或组合的免疫原性和保护效力。所有mRNA候选疫苗均可引发潜在的抗原特异性体液和细胞免疫应答，并提供针对牛痘病毒（VACV）感染的保护作用。两种二价mRNA疫苗和四价疫苗组合的保护效果优于单独的二价mRNA疫苗。我们的研究为开发更有效，更安全的mRNA疫苗提供了有价值的见解。
